Immunome Inc.
For the period ended Jun 9, 2026. Filed Apr 24, 2026.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Jun 9, 2026 · Filed Apr 24, 2026
Contents
Cover page
Show cover page
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No. )
Filed by the Registrant ☒
Filed by a party other than the Registrant ☐
| Check the appropriate box: | |
|---|---|
| ☐ | Preliminary Proxy Statement |
| ☐ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ☒ | Definitive Proxy Statement |
| ☐ | Definitive Additional Materials |
| ☐ | Soliciting Material under § 240.14a-12 |
Immunome, Inc.
(Name of Registrant as Specified in Its Charter)
(Name of Person(s) Filing Proxy Statement if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
| ☒ | No fee required |
|---|---|
| ☐ | Fee paid previously with preliminary materials |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 |
April 24, 2026
Dear Stockholder:
This year was a defining one for Immunome, Inc., where disciplined execution drove pipeline advancement and clinical progress. We ended 2025 with positive data from the Phase 3 RINGSIDE trial of varegacestat in patients with progressing desmoid tumors. This milestone underscores the strength of our focused organization and caps a year of consistent delivery across our pipeline and platform. The doubling of our share price between January and December 2025 reflects the market’s recognition of our performance. We are committed to delivering on our potential in 2026 and beyond.
Central to our progress is varegacestat. Successful execution of the Phase 3 RINGSIDE trial and completion of critical manufacturing and non-clinical pharmacology activities position us to support our planned NDA filing in the second quarter of 2026. In 2025, we made significant progress advancing our antibody-drug conjugate (ADC) portfolio, including initiation of a Phase 1 trial of IM-1021 and continued preclinical development of IM-1617, IM-1340 and IM-1335. Each of these ADC programs incorporates our proprietary TOP1 inhibitor payload (HC74) and is designed with a differentiated profile to address unmet need and provide first- and/or best-in-class potential. We also received IND clearance for IM-3050, our potentially best-in-class radioligand therapy targeting FAP. Together, these assets position us to drive improved patient outcomes while creating meaningful long-term value for our stockholders.
Building a sustainable, industry-leading oncology company requires execution year in and year out. Our 2025 achievements were set in motion in prior years, and they now provide the foundation for a productive 2026. This year, we plan to present detailed data from the Phase 3 RINGSIDE trial as we continue to prepare varegacestat for approval and launch. We also anticipate sharing initial lymphoma data for IM-1021. Our investments in ADC discovery and preclinical development position our pipeline for a transformative year, with IND submissions planned for IM-1617, IM-1340 and IM-1335 over the course of 2026. We also expect to imminently dose our first patient in the Phase 1 trial of IM-3050.
Our executive compensation program is designed to align pay with performance and long-term stockholder value creation, with a substantial majority of compensation tied to the achievement of key corporate objectives. The compensation outcomes for 2025 reflect this performance-based approach. We believe our program appropriately aligns management incentives with the interests of our stockholders and supports long-term value creation.
We remain focused on realizing the full potential of our pipeline for patients and stockholders. The matters to be considered at the Annual Meeting reflect our focus on governance, accountability and alignment with stockholder interests.
Immunome, Inc.’s 2026 Annual Meeting of Stockholders will be held at 12:00 p.m. Eastern Time, on Tuesday, June 9, 2026. The meeting will be conducted entirely online via a live audio webcast. We believe that hosting the Annual Meeting virtually will enable greater stockholder attendance and participation and improve our ability to communicate more effectively with our stockholders. Stockholders will have the same rights and opportunities to participate as they would at an in-person meeting. The meeting can be accessed via the Internet atwww.virtualshareholdermeeting.com/IMNM2026.
Details regarding the business to be conducted at the Annual Meeting are more fully described in the accompanying Notice of 2026 Annual Meeting of Stockholders and 2026 Annual Meeting Proxy Statement. Other than the proposals described in the Proxy Statement, the Board of Directors of Immunome, Inc. is not aware of any other matters to be presented for a vote at the Annual Meeting. Under U.S. Securities and Exchange Commission rules that allow companies to furnish proxy materials over the Internet, we have elected to deliver our proxy materials to the majority of our stockholders over the Internet. This delivery process allows us to provide stockholders with the information they need, while at the same time conserving natural resources and lowering the cost of delivery.
Your vote is important. Whether or not you plan to virtually attend the Annual Meeting, we hope you will vote as soon as possible. Information about voting methods is set forth in the accompanying Notice and Proxy Statement.
If you have any questions regarding voting, please call our Corporate Secretary at 425-939-7410.
Sincerely,
/s/ Clay B. Siegall
Clay B. Siegall, Ph.D.
Chairman of the Board, President and Chief Executive Officer
18702 N. Creek Parkway, Suite 100
Bothell, Washington 98011
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
To Be Held on June 9, 2026
Dear Stockholder:
You are cordially invited to attend the Annual Meeting of Stockholders (the “Annual Meeting”) of Immunome, Inc., a Delaware corporation (the “Company”). The Annual Meeting will be held on Tuesday, June 9, 2026, at 12:00 p.m. Eastern Time. The Annual Meeting will be a virtual meeting of stockholders, which will be conducted only via a live audio webcast. You will be able to attend the Annual Meeting, submit any questions and vote online during the meeting by visitingwww.virtualshareholdermeeting.com/IMNM2026. The Annual Meeting will be held for the following purposes:
| 1. | To elect the three nominees named in the Proxy Statement accompanying this Notice to serve as Class III directors, to hold office until the 2029 Annual Meeting of Stockholders and such time as their successors are duly elected and qualified, or until their respective earlier death, resignation or removal. |
| 2. | To ratify the appointment of Ernst & Young LLP as Immunome, Inc.’s independent registered public accounting firm for the fiscal year ending December 31, 2026 by the Audit Committee of the Board of Directors of the Company. |
| 3. | To approve, on an advisory basis, the compensation of the Company’s Named Executive Officers, as disclosed in the Proxy Statement accompanying this Notice. |
| 4. | To indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company’s Named Executive Officers. |
| 5. | To conduct any other business properly brought before the Annual Meeting. |
These items of business are more fully described in the Proxy Statement accompanying this Notice.
The Annual Meeting will be held virtually through a live audio webcast. Stockholders of record at the close of business on April 16, 2026 and their proxy holders will be able to attend the Annual Meeting, submit questions and vote during the live audio webcast by visitingwww.virtualshareholdermeeting.com/IMNM2026 and entering the 16-digit Control Number included in the Notice of Internet Availability or in the instructions that you received via email. Please refer to the additional logistical details and recommendations in the accompanying Proxy Statement. You may log in beginning at 11:45 a.m. Eastern Time, on June 9, 2026.
Only stockholders of record at the close of business on April 16, 2026 and their proxy holders may vote at the Annual Meeting or any adjournment thereof.
Important Notice Regarding the Availability of Proxy Materials for the
Annual Meeting of Stockholders to Be Held On
Tuesday, June 9, 2026 at 12:00 p.m. Eastern Time at
www.virtualshareholdermeeting.com/IMNM2026.
The proxy statement and annual report to stockholders are available at
https://investors.immunome.com/sec-filings/.
By Order of the Board of Directors
/s/ Clay B. Siegall
Clay B. Siegall, Ph.D.
Chairman of the Board, President and Chief Executive Officer
Bothell, WA
You are cordially invited to attend the Annual Meeting online. Whether or not you expect to attend the meeting, please vote over the telephone or the Internet as instructed in these materials, or, if you receive a paper proxy card by mail, by completing and returning the proxy card mailed to you, as promptly as possible to ensure your representation at the meeting. Even if you have voted by proxy, you may still vote online if you attend the meeting.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.